Original croissant meter intranet
Highlights
On April 16, according to the official website of the NMPA, Qilu Pharmaceutical's cetrorelix acetate for injection was approved for marketing and regarded as the sixth domestic company. Cetrorelix acetate for injection is an assisted reproductive drug, with terminal sales of more than 300 million yuan in China's public medical institutions in 2022.
Cetrorelix acetate for injection is a third-generation gonadotropin-releasing hormone antagonist drug, which has a rapid onset of action at 1 hour and prevents LH elevation throughout the day, and is used in antagonist regimens to effectively prevent the occurrence of ovarian hyperstimulation. The indication of this product is: in assisted reproductive technology, for patients with controlled ovarian stimulation, this product can prevent early ovulation.
According to data from Minenet, in 2022, the sales of cetrorelix acetate for injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (hereinafter referred to as China's public medical institutions) will exceed 300 million yuan, and its sales will exceed 150 million yuan in the first half of 2023, a year-on-year increase of 8.96%.
Sales of cetrorelix acetate for injection in terminal medical institutions in China (unit: 10,000 yuan)
Source: Minenet's competitive landscape of drug terminals in China's public medical institutions
In addition to the original manufacturer Merck, the domestic market also has Ferring Pharmaceutical, Livzon Group, Jinsai Pharmaceutical, Hainan Tiansheng Baohe, Hainan Zhonghe Pharmaceutical Co., Ltd. cetrorelix acetate for injection has been approved for marketing, and Qilu Pharmaceutical is the sixth domestic manufacturer of this product.
Since 2024, Qilu Pharmaceutical has been approved as a product
Source: Minenet China Declaration Progress (MED) database
Since the beginning of this year, Qilu Pharmaceutical has approved 6 varieties for marketing, including eltrombopag ethanolamine tablets, mirabegron sustained-release tablets, azacitidine for injection, cefopodoxime late dry suspension, cetrorelix acetate for injection, cefaclor capsules, etc., further enriching the company's product line.
Source: Minenet database, NMPA
Note: The statistical scope of "Drug Terminal Competition Pattern of China's Public Medical Institutions" by Minenet is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics and village clinics, and the above sales are calculated based on the average retail price of products at the terminal.